

Human Fractalkine



www.mesoscale.com®

Ordering Information

MSD Customer Service
Phone: 1-240-314-2795
Fax: 1-301-990-2776
Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
Email: ScientificSupport@mesoscale.com


Company Address

MESO SCALE DISCOVERY®
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K15067M, K25067M	U-PLEX Biomarker Group 1 (hu)
	K151AEM, K251AEM	U-PLEX Immuno-Oncology Group 1 (hu)
	K151ACM, K251ACM	U-PLEX Metabolic Group 1 (hu)
Singleplex	K151VCK-1/-2/-4	U-PLEX Human Fractalkine Assay with SECTOR™ plates
	K151VCK-21/-22/-24	U-PLEX Human Fractalkine Assay with QuickPlex® plates
	K251VCK-2/-4	U-PLEX Human Fractalkine Assay with 384-well plates
Antibody Set	B21VC-2/-3	U-PLEX Human Fractalkine Antibody Set
Protocol	U-PLEX Product Inserts are available at http://www.mesoscale.com	

The U-PLEX® platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX Human Fractalkine Assay tested on U-PLEX 96-well plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
Fractalkine	102	75-215

The Calibrator curve was fitted with a 4-parameter logistic model with a 1/Y² weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	19,900	4.2	8.3
Mid	8,220	4.2	8.5
Low	274	18.0	27.4

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

For Research Use Only.
Not for use in diagnostic procedures.

MSD® U-PLEX Human Fractalkine

Tested Samples

Sample Type	Serum (N=10)	Plasma (N=10)	Spiked Plasma (N=5)	Spiked Serum (N=5)
Median (pg/mL)	4,130	3,940	3,300	4,050
Range (pg/mL)	3,350-8,790	1,580-4,960	2,680-3,960	3,690-6,330
% Detected	100	100	100	100

Normal serum and plasma samples were diluted 4-fold prior to the assay.

Dilution Linearity

Serum			EDTA Plasma		
Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
2	82	64-95	2	95	91-99
4	85	67-101	4	93	87-101
8	80	54-97	8	87	82-99

Normal human serum and EDTA plasma were spiked with Calibrator and tested at different dilutions. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Spike Recovery

Spike Level	Serum		EDTA Plasma	
	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	113	75-106	123	85-121
Mid	109	80-108	116	90-111
Low	105	77-94	109	83-95

Normal serum and plasma were spiked with Calibrator at 3 levels. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Specificity

To assess specificity, the Fractalkine Antibody Set was tested individually against a larger panel of analytes for nonspecific binding (APRIL/TNFSF13, BAFF, BAFF-R/TNFSF13C, BCMA/TNFSF17, BDNF, C-Peptide, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, Desghrelin, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FGF-21, FGF-23, FLT3L, Fractalkine, FSH, Galectin-9, G-CSF, GITRL/TNFSF18, GTR/TNFSF18, Ghrelin (Ser3-octanoylated), gp130 (soluble), GIP (1-42), GIP (3-42), GLP-1 (7-36), GLP-1 (9-36), Glucagon, GM-CSF, Granzyme A, Granzyme B, GRO- α , HAVCR2/TIM-3, HVEM/TNFSF14, ICOS, ICOS-L/B7-H2, I-309, IFN- α 2a, IFN- β , IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-2, IL-2R α , IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN- λ 1, IL-31, IL-33, Insulin, IP-10, LAG3, Leptin, LH, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1 α , MIP-1 β , MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PIGF, PP, Proinsulin, proMMP-9, P-Selectin, PYY (3-36), RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, SDF-1 α , Tie-2, TIGIT, TLR1, TNF- α , TNF- β , TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40, and β -NGF). Nonspecific binding was less than 2.0%.

$$\% \text{ Nonspecificity} = (\text{nonspecific signal} / \text{specific signal}) \times 100$$

Diluent Compatibility

Diluents 57 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: Fractalkine is included in Calibrator 4. The Fractalkine Calibrator is a full-length recombinant protein expressed in mouse cells.

Antibodies: The U-PLEX Human Fractalkine Assay uses a mouse monoclonal antibody for capture and a goat polyclonal antibody for detection.

Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.

